Tiziana Life Sciences (TLSA) Stock Price, News & Analysis

Company Overview

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Key Stats

• Today's Range: $1.02 to $1.12
• 50-Day Range: $0.64 to $1.69
• 52-Week Range: $0.41 to $1.91
• Volume: 143,508 shs
• Average Volume: 450,061 shs
• Market Capitalization: $122.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Tiziana Life Sciences Stock Analysis - MarketRank™

Tiziana Life Sciences scored higher than 13% of companies evaluated by MarketBeat, and ranked 901st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Tiziana Life Sciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Tiziana Life Sciences has a P/B Ratio of 21.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 42.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tiziana Life Sciences does not currently pay a dividend.

Dividend Growth

Tiziana Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.13% of the float of Tiziana Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Tiziana Life Sciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tiziana Life Sciences has recently increased by 42.46%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.76

News Sentiment

Tiziana Life Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Tiziana Life Sciences this week, compared to 1 article on an average week.

Search Interest

Only 6 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

MarketBeat Follows

5 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

TLSA Stock Analysis - Frequently Asked Questions

How have TLSA shares performed this year?

Tiziana Life Sciences' stock was trading at $0.6962 at the beginning of the year. Since then, TLSA stock has increased by 51.5% and is now trading at $1.0550.
View the best growth stocks for 2025 here.

When did Tiziana Life Sciences IPO?

Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO) and Pfizer (PFE).

Company Calendar

• Today: 4/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLSA
• CIK: 1723069
• Web: www.tizianalifesciences.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 21.60

Miscellaneous

• Outstanding Shares: 116,848,000
• Free Float: 63,427,000
• Market Cap: $126.20 million
• Optionable: Optionable
• Beta: 0.48